TRIM33 and dermatomyositis: Significantly higher levels of plasma VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ were observed among Cancer TIF1-γ-DM patients, especially among untreated Cancer TIF1-γ-DM patients.